TiumBio Co., Ltd.
TiumBio is a biopharmaceutical company developing rare-disease drug candidates NCE401, NCE403, NBP604, and TU2218.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureTiumBio was founded in 2016 and listed on KOSDAQ in 2019 as a company developing treatments for rare and intractable diseases. It is developing the small-molecule candidates NCE401 and NCE403, the biologic candidate NBP604, and TU2218, a dual TGF-β/VEGF inhibitor, while running a CDAO business through subsidiary Protium Science and a natural cosmetics OEM/ODM business through Petraon Care Lab. Petraon Care Lab, serving clients such as Ananti and Tone28, grew revenue from about KRW 3.6 billion in 2024 to about KRW 4.9 billion in 2025, and Protium Science was established in May 2021 as a dedicated CDAO company.
Products & technology
- TU2218Dual TGF-β/VEGF signaling inhibitor candidate for cancer and fibrosis
- NCE401
- NCE403
- NBP604
Clinical trials
data.go.kr3 MFDS clinical trial authorisations · 2021–2023 (Phase 1/2a 1 · Phase 1 1 · Phase 1/2 1)
- Phase 1/2aTU22182023-05-22
9 trial sites
- Phase 1TU77102023-04-03
1 trial site
- Phase 1/2TU22182021-12-30
2 trial sites
AI reads
MAA server logs · IP-verifiedSomeone asked an AI a question, and it fetched this page live to answer.
Collected for later use. Not a signal of interest.
- OpenAIChatGPT-Useranswer2
- OpenAIOAI-SearchBot2
Measured since Aug 26, 2026 · 1 AI engines · last read Aug 26, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS.
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition